Topical Cranial Nerve Activation for Neurodegenerative Symptom Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative disorders, such as Parkinson's disease and essential tremor, are invasive, have significant side effects, and do not effectively address motor and non-motor symptoms, lacking specificity towards neural targets.
Innovation Solution
A method involving the topical administration of sex steroids like progesterone or testosterone, and cannabinoids like dronabinol, to specific areas of the skin to activate cranial nerves, thereby treating motor and non-motor symptoms without systemic absorption, allowing for non-invasive and targeted pharmacological treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for neurodegenerative disorders are used, then motor and non-motor symptoms can be addressed, but the treatments are invasive and have significant side effects
Solution Approach 1:
The patent uses the skin as an intermediary medium to deliver pharmacological agents to cranial nerves. Instead of directly administering drugs systemically or invasively stimulating the brain, the invention applies compounds topically to the skin, which then activates cranial nerves as intermediaries to produce therapeutic effects in the brain and nervous system, thereby reducing side effects while maintaining treatment effectiveness
Solution Approach 2:
The patent replaces mechanical/invasive stimulation methods (such as deep brain stimulation requiring surgical implantation of electrodes) with pharmacological activation through topical application. This substitution eliminates the need for invasive procedures while achieving similar therapeutic goals through chemical activation of cranial nerves
2Reliability
If current treatments are used, then symptoms can be managed, but they lack specificity towards neural targets
Solution Approach 1:
The patent applies pharmacological agents locally to specific skin areas that correspond to the distribution of cranial nerves, rather than systemic administration. This localized application ensures that the compounds activate specific cranial nerves and their associated neural pathways, providing targeted therapy for specific symptoms while avoiding unnecessary systemic effects
Solution Approach 2:
The patent segments the treatment approach by targeting individual cranial nerves (such as the trigeminal, facial, or vagus nerves) based on the specific symptoms present. Different skin areas correspond to different cranial nerve distributions, allowing selective activation of specific neural pathways to address motor symptoms, non-motor symptoms, or cognitive deficits independently
3Duration of action of moving object
If topical administration of sex steroids and cannabinoids is used, then rapid and sustained symptom relief is achieved, but the mechanism involves non-invasive neural signaling
Solution Approach 1:
The patent employs compounds that bind to endogenous receptors (such as cannabinoid receptors or steroid hormone receptors) already present in the skin and neural tissue. The body's own receptor systems mediate the therapeutic effect, eliminating the need for complex delivery devices or invasive procedures. The pharmacological agents leverage the body's existing biological infrastructure to produce sustained symptom relief
Data Source
Figure 1
Figure 2
AI summary
A method for treating a symptom of a neurodegenerative condition. The method includes topically administering a composition that contains a sex steroid or a cannabinoid or a mixture of both to to the forehead, to an area of the outer ear of the subject not including the ear canal, or to both of these anatomical locations The symptom treatable by the method is a motor symptom or a non-motor symptom.